ontozry
angelini pharma s.p.a - cenobamate - epilepsie - antiepileptika, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.
skytrofa (previously lonapegsomatropin ascendis pharma)
ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hypofýzy a hypotalamické hormony a analogy - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.
arutimol 5mg/ml oční kapky, roztok
bausch + lomb ireland limited, dublin array - 2696 timolol-maleinÁt - oční kapky, roztok - 5mg/ml - timolol
dituzdin 6mg/ml perorální roztok
teva b.v., haarlem array - 5810 levodropropizin - perorální roztok - 6mg/ml - levodropropizin
dituzdin 60mg potahovaná tableta
teva b.v., haarlem array - 5810 levodropropizin - potahovaná tableta - 60mg - levodropropizin
ztalmy
marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - jiná antiepileptika - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.